142 related articles for article (PubMed ID: 10211310)
21. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
22. MDM2 overexpression with alteration of the p53 protein and gene status in oral carcinogenesis.
Li XJ; Murai M; Koyama T; Wang DY; Hashimoto K
Jpn J Cancer Res; 2000 May; 91(5):492-8. PubMed ID: 10835493
[TBL] [Abstract][Full Text] [Related]
23. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
24. C-deletion mutation of the p53 gene at exon 4 of codon 63 in the saliva of oral squamous cell carcinoma in central India: a preliminary study.
Mewara A; Gadbail AR; Patil S; Chaudhary M; Chavhan SD
J Investig Clin Dent; 2010 Nov; 1(2):108-13. PubMed ID: 25427266
[TBL] [Abstract][Full Text] [Related]
25. Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression.
Shindoh M; Chiba I; Yasuda M; Saito T; Funaoka K; Kohgo T; Amemiya A; Sawada Y; Fujinaga K
Cancer; 1995 Nov; 76(9):1513-21. PubMed ID: 8635051
[TBL] [Abstract][Full Text] [Related]
26. RT-PCR amplification of RNA extracted from formalin-fixed, paraffin-embedded oral cancer sections: analysis of p53 pathway.
Tachibana M; Shinagawa Y; Kawamata H; Omotehara F; Horiuchi H; Ohkura Y; Kubota K; Imai Y; Fujibayashi T; Fujimori T
Anticancer Res; 2003; 23(3C):2891-6. PubMed ID: 12926130
[TBL] [Abstract][Full Text] [Related]
27. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
29. A multiple primary carcinoma consisting of leukoplakia and SCC: a case report with p53 mutation analysis.
Hassan NM; Tada M; Shindoh M; Hamada J; Kashiwazaki H; Shimo T; Ashikaga Y; Yamazaki Y; Sasaki A; Moriuchi T; Inoue N
Anticancer Res; 2010 Nov; 30(11):4773-8. PubMed ID: 21115940
[TBL] [Abstract][Full Text] [Related]
30. Expression of p21/waf1 in oral squamous cell carcinomas--correlation with p53 and mdm2 and cellular proliferation index.
Ng IO; Lam KY; Ng M; Regezi JA
Oral Oncol; 1999 Jan; 35(1):63-9. PubMed ID: 10211312
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of mutations in the p53 gene of oral squamous-cell carcinomas associated with betel-quid chewing in Sri Lanka.
Chiba I; Muthumala M; Yamazaki Y; Uz Zaman A; Iizuka T; Amemiya A; Shibata T; Kashiwazaki H; Sugiura C; Fukuda H
Int J Cancer; 1998 Sep; 77(6):839-42. PubMed ID: 9714051
[TBL] [Abstract][Full Text] [Related]
32. Expression of p53, PCNA, Ki-67 and bcl-2 in relation to risk factors in oral cancer - a molecular epidemiological study.
Schildt EB; Nylander K; Eriksson M; Hardell L; Magnusson A; Roos G
Int J Oncol; 2003 Apr; 22(4):861-8. PubMed ID: 12632080
[TBL] [Abstract][Full Text] [Related]
33. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
35. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
37. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck.
Nylander K; Dabelsteen E; Hall PA
J Oral Pathol Med; 2000 Oct; 29(9):413-25. PubMed ID: 11016683
[TBL] [Abstract][Full Text] [Related]
38. p53 mutations and human papillomavirus DNA in oral squamous cell carcinoma: correlation with apoptosis.
Koh JY; Cho NP; Kong G; Lee JD; Yoon K
Br J Cancer; 1998 Aug; 78(3):354-9. PubMed ID: 9703282
[TBL] [Abstract][Full Text] [Related]
39. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
40. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
